Glycemic Control and Cardiovascular Disease in 7,454 Patients With Type 1 Diabetes
An observational study from the Swedish National Diabetes Register (NDR)
- Katarina Eeg-Olofsson, MD1,
- Jan Cederholm, MD, PHD2,
- Peter M. Nilsson, MD, PHD3,
- Björn Zethelius, MD, PHD4,
- Ann-Marie Svensson, RN, PHD5,
- Soffia Gudbjörnsdóttir, MD, PHD1 and
- Björn Eliasson, MD, PHD1
- 1Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Göteborg, Sweden;
- 2Department of Public Health and Caring Sciences/Family Medicine and Clinical Epidemiology, Uppsala University, Uppsala, Sweden;
- 3Department of Clinical Sciences, Lund University, University Hospital, Malmö, Sweden;
- 4Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden;
- 5Center of Registers in Region Västra Götaland, Göteborg, Sweden.
- Corresponding author: Katarina Eeg-Olofsson, katarina.eeg-olofsson{at}vgregion.se.
Abstract
OBJECTIVE We assessed the association between A1C and cardiovascular diseases (CVDs) in an observational study of patients with type 1 diabetes followed for 5 years.
RESEARCH DESIGN AND METHODS A total of 7,454 patients were studied from the Swedish National Diabetes Register (aged 20–65 years, diabetes duration 1–35 years, followed from 2002 to 2007).
RESULTS Hazard ratios (HRs) for fatal/nonfatal coronary heart disease (CHD) per 1% unit increase in baseline or updated mean A1C at Cox regression analysis were 1.31 and 1.34 and 1.26 and 1.32, respectively, for fatal/nonfatal CVD (all P < 0.001 after adjustment for age, sex, diabetes duration, blood pressure, total and LDL cholesterol, triglycerides, BMI, smoking, and history of CVD). HRs were only slightly lower for CHD (P = 0.002) and CVD (P = 0.002–0.007) after also adjusting for albuminuria. Adjusted 5-year event rates of CHD and CVD increased progressively with higher A1C, ranging from 5 to 12%, as well as when subgrouped by shorter (1–20 years) or longer (21–35 years) duration of diabetes. A group of 4,186 patients with A1C 5–7.9% (mean 7.2) at baseline showed risk reductions of 41% (95% confidence intervals: 15–60) (P = 0.005) for fatal/nonfatal CHD and 37% (12–55) (P = 0.008) for CVD, compared with 3,268 patients with A1C 8–11.9% (mean 9.0), fully adjusted also for albuminuria.
CONCLUSIONS This observational study of patients in modern everyday clinical practice demonstrates progressively increasing risks for CHD and CVD with higher A1C, independently of traditional risk factors, with no J-shaped risk curves. A baseline mean A1C of 7.2% showed considerably reduced risks of CHD and CVD compared with A1C 9.0%, emphasizing A1C as a strong independent risk factor in type 1 diabetes.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
- Received March 1, 2010.
- Accepted April 17, 2010.
- © 2010 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
